Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14302203 | 0.84 | ADORA3 (0.40) | BACE1ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL498744 | 0.83 | GCGR (0.38) | KDM4EPOLBTSHRGCGRALDH1A1 | |
| SCHEMBL10015874 | 0.74 | RAD52 (0.32) | — | |
| SCHEMBL499037 | 0.65 | HIF1A (0.36) | KDM4EPOLB | |
| SCHEMBL2914750 | 0.65 | TNKS2 (0.51) | BACE1ESR2ALOX5ALDH1A1 | |
| SCHEMBL11978812 | 0.65 | GCGR (0.54) | GCGR | |
| SCHEMBL2916168 | 0.62 | TNKS2 (0.49) | BACE1ADORA2AADORA1ESR2 | |
| SCHEMBL15811744 | 0.62 | HTT (0.49) | KDM4ETSHR | |
| SCHEMBL2914384 | 0.62 | BACE1 (0.70) | BACE1KDM4EALOX5ALDH1A1 | |
| SCHEMBL1535892 | 0.62 | DPP4 (0.54) | POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-8106089-B2 | Reacting pyrrolylalkylcarbinole, furanylalkylcarbinole or thiophenylalkylcarbinole units; cyclodehydration, hydroboration, oxidation, palladium-catalyzed Suzuki-Miyaura cross-coupling; anticarcinogenic agents, antitumor, and antiproliferative agents; autoimmune and neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE (FR) | 2012-01-31 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | UNIVERSITE DE RENNES (FR) | 2008-11-06 | — | — | US | disclosed |
| EP-1751100-B1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NAT RECH SCIENT (FR) | 2008-01-09 | — | — | EP | disclosed |
| EP-1751100-B1 | ANTI-TUBULIN ACTING ARYLPYRROL, ARYLFULRAN AND ARYLTHIOPENE DERIVATIVES, METHOD FOR THE PREPARATION AND USE THEREOF AS AN ANTIMITOTIC | CENTRE NAT RECH SCIENT (FR) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275103-A1 | Anti-Tubulin Acting Arylpyrrol, Arylfuran And Arylthiophene Derivatives, Method For The Preparation Thereof And For The Use Thereof As An Antimitotic | TUBB1, TUBB3, TUBB | BACE1 2543/4885KDM4E 4004/4885POLB 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.